ImmunoCellular Therapeutics (MKT:IMUC) said U.S. Food and Drug Administration gave clearance Wednesday to start Phase I clinical trials of ICT-121, a vaccine that targets an antigen expressed in tumours.
The trial, which will
be performed at a Los Angeles-based medical centre, will test the
vaccine on 20 patients with glioblastoma multiforme, an aggressive brain
Like ICT-107, now in Phase II trials treating subjects
with the same type of brain cancer, the ICT-121 treatment is the second
dendritic cell-based vaccine to enter the clinic.
tumour vaccines work by turning a patient’s immune system against tumour
associated antigens. This is done by pulling out dendritic cells and
loading them with antigens. The cells, then, are reinserted into the
patient’s body to trigger an immune response.
studies indicate ICT-121 effectively targets CD-133, a protein that is
over-expressed by a wide range of solid tumours,” ImmunoCellular's chief
executive Manish Singh said in a statement.
The company said
that it is eager to continue evaluating an immunotherapeutic approach to
cancer treatment, given the highly encouraging survival benefit seen in
patients treated with ICT-107.
The company seeks to develop and
sell new therapeutics using the immune system to fight cancer.
ImmunoCellular is based in Los Angeles.